公开(公告)号：CA2355283A1

公开(公告)日：2000-06-22

申请号：CA2355283

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： ROSE LYNN M ,  PORUBEK DAVID J ,  MONTGOMERY ALAN B

IPC: C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18 ,  A01N43/40 ,  A61K31/44

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused b y Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex , infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacteri al infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

公开(公告)号：PL348812A1

公开(公告)日：2002-06-17

申请号：PL34881299

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  BAKER WILLIAM R

IPC: A61K20060101 ,  A61K9/00 ,  A61K9/12 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.

公开(公告)号：AU730546B2

公开(公告)日：2001-03-08

申请号：AU5790998

申请日：1997-11-13

Applicant: PATHOGENESIS CORP

Inventor： VANDEVANTER DONALD R ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K38/00 ,  A61K38/12 ,  A61P11/00 ,  A61P31/04 ,  C07K7/50 ,  C07K7/62 ,  A61K31/00

公开(公告)号：CA2179305C

公开(公告)日：2000-10-31

申请号：CA2179305

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDREN S HOSPITAL & MEDICAL

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100 % of susceptible bacteria. Aminoglycoside is formulated in 5 ml solution of a quater normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 .mu., produced by a jet or ultrasonic nebulizer.

公开(公告)号：GR3031770T3

公开(公告)日：2000-02-29

申请号：GR990402861

申请日：1999-11-05

Applicant: PATHOGENESIS CORP ,  CHILDRENS HOSP MEDICAL CENTER

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.

公开(公告)号：CA2355283C

公开(公告)日：2009-02-17

申请号：CA2355283

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  PORUBEK DAVID J ,  ROSE LYNN M

IPC: A61K31/5383 ,  C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

公开(公告)号：BR9916296A

公开(公告)日：2004-06-29

申请号：BR9916296

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  BAKER WILLIAM R

IPC: A61K9/12 ,  A61K20060101 ,  A61K9/00 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.

公开(公告)号：HU0105226A2

公开(公告)日：2002-04-29

申请号：HU0105226

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  MONTGOMERY ALAN B

IPC: A61K20060101 ,  A61K9/12 ,  A61K9/00 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: A tal lm ny t rgy t egy, a súlyos krónikus bronchitis (bronchiectasia)kezelésére szolg ló elj r s képezi, mely egy koncentr lt antibiotikum-készítményt alkalmaz, mely az antibiotikumot a tüdő alveolusokat istartalmazó endobronchi lis terébe juttatja egy aeroszol vagy egy szraz por alakj ban, melynek t"meg tlagos tmérője túlnyomórészt 1 és 5mikron k"z"tt van. Az elj r s sor n az antibiotikumot olyan koncentrcióban alkalmazz k, mely 1-10000-szer magasabb, mint a célszervbenmért minim lis inhibitor-koncentr ció. Előny"sen, az elj r s sor n azaeroszol vagy sz raz por alakban lévő tobramycint endobronchi lisanjuttatj k be a pseudomonas-fertőzések kezelésére a súlyos krónikusbronchitisben (bronchiectasi ban) szenvedő betegeknél. Ó

公开(公告)号：AT202481T

公开(公告)日：2001-07-15

申请号：AT97954029

申请日：1997-11-13

Applicant: PATHOGENESIS CORP

Inventor： VANDEVANTER DONALD R ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K38/00 ,  A61K38/12 ,  A61P11/00 ,  A61P31/04 ,  C07K7/50 ,  C07K7/62 ,  A61K38/08

公开(公告)号：DE69511374T2

公开(公告)日：2000-02-24

申请号：DE69511374

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDREN S HOSPITAL AND REGION

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.